The rising interest in GLP-1 agonists for diabetes has sparked a question about application forms : transdermal systems versus tablets . Traditionally , GLP-1 therapies were exclusively available in oral form, but the development of transdermal delivery presents a alternative option . Patches might suit individuals facing difficulty swallowing pill